Blackstone Inc’s ACELYRIN SLRN Stock Holding History

Blackstone Inc’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-175,000	Closed	-$3.66M	–	166
2023 Q2	$3.66M	Buy	+175,000	New	+$3.58M	0.02%	98

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Blackstone Inc's SLRN Position: Q3 2023 in Review

Blackstone Inc sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 175,000 shares — an estimated $3.66M sold.

Blackstone Inc first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $3.66M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

Blackstone Inc reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
Blackstone Inc sold 175,000 ACELYRIN shares in Q3 2023, an estimated $3.66M.
Blackstone Inc first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
Blackstone Inc's ACELYRIN position peaked at $3.66M in Q2 2023.
101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Blackstone Inc's 13F filing for Q3 2023, filed 14 Nov 2023.